An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
Top results in this bookTable of Contents
Visual Dysfunction in Patients with Traumatic Brain Injury: A Systematic Review [Internet].
O'Neil M, Gleitsmann K, Motu'apuaka M, et al.
Washington (DC): Department of Veterans Affairs (US); 2014 Sep.
Video Displays, Work, and Vision.
National Research Council (US) Panel on Impact of Video Viewing on Vision of Workers; National Research Council (US) Committee on Vision.
Washington (DC): National Academies Press (US); 1983.
Making Eye Health a Population Health Imperative: Vision for Tomorrow.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on Public Health Approaches to Reduce Vision Impairment and Promote Eye Health; Welp A, Woodbury RB, McCoy MA, et al., editors.
Washington (DC): National Academies Press (US); 2016 Sep 15.
Screening for Visual Impairment in Children Ages 1-5 Years: Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation [Internet].
Chou R, Dana T, Bougatsos C.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Feb. (Evidence Syntheses, No. 81.)
GeneReviews® [Internet].
Adam MP, Feldman J, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2025.
Evaluation of the Disability Determination Process for Traumatic Brain Injury in Veterans.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services; Committee on the Review of the Department of Veterans Affairs Examinations for Traumatic Brain Injury.
Washington (DC): National Academies Press (US); 2019 Apr 10.
Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition.
Walker HK, Hall WD, Hurst JW, editors.
Boston: Butterworths; 1990.
Myopia: Causes, Prevention, and Treatment of an Increasingly Common Disease.
National Academies of Sciences, Engineering, and Medicine; Division of Behavioral and Social Sciences and Education; Board on Behavioral, Cognitive, and Sensory Sciences; Committee on Focus on Myopia: Pathogenesis and Rising Incidence.
Washington (DC): National Academies Press (US); 2024 Sep 17.
Neuroscience. 2nd edition.
Purves D, Augustine GJ, Fitzpatrick D, et al., editors.
Sunderland (MA): Sinauer Associates; 2001.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
York (UK): Centre for Reviews and Dissemination (UK); 1995-.
The Neural Bases of Multisensory Processes.
Murray MM, Wallace MT, editors.
Boca Raton (FL): CRC Press/Taylor & Francis; 2012.
An external pilot study to test the feasibility of a randomised controlled trial comparing eye muscle surgery against active monitoring for childhood intermittent exotropia [X(T)].
Clarke M, Hogan V, Buck D, et al.
Southampton (UK): NIHR Journals Library; 2015 May. (Health Technology Assessment, No. 19.39.)
Aflibercept (Eylea HD): Therapeutic area: Diabetic Macular Edema: Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Nov.
Aflibercept 8 mg (0.07 mL) (Eylea HD): Therapeutic area: Macular degeneration, age-related: Reimbursement Review [Internet].
Dyslexia Dysorthography Dyscalculia: Review of the scientific data [Internet].
INSERM Collective Expertise Centre.
Paris (FR): Institut national de la santé et de la recherche médicale; 2007.
Faricimab (Vabysmo): CADTH Reimbursement Review: Therapeutic area: Macular degeneration, age-related [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.
A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN).
Chakravarthy U, Harding SP, Rogers CA, et al.; for the IVAN Investigators.
Southampton (UK): NIHR Journals Library; 2015 Oct. (Health Technology Assessment, No. 19.78.)
Faricimab (Vabysmo): CADTH Reimbursement Review: Therapeutic area: Diabetic macular edema [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jan.
Tralokinumab (Adtralza): Therapeutic area: Atopic dermatitis: CADTH Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Sep.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on